We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$65.3M
Cap. Flow
+$26.2M
Cap. Flow %
5.96%
Top 10 Hldgs %
48.81%
Holding
93
New
22
Increased
21
Reduced
16
Closed
33

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$33.8M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$24.3M
3
AGN
Allergan plc
AGN
+$16M
4
CCI icon
Crown Castle
CCI
+$10.7M
5
ANDV
Andeavor
ANDV
+$10.7M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$16.1M
2
CAM
CAMERON INTERNATIONAL CORPORATION
CAM
+$11M
3
DG icon
Dollar General
DG
+$10.8M
4
PARA
Paramount Global Class B
PARA
+$10.3M
5
CMI icon
Cummins
CMI
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 34.64%
2 Communication Services 13.84%
3 Real Estate 10.92%
4 Energy 8.35%
5 Industrials 8.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
51
Illumina
ILMN
$29.3B
$328K 0.07%
+3,049
New +$279K
MYGN icon
52
Myriad Genetics
MYGN
$304M
$269K 0.06%
12,813
+8,283
+183% +$209K
BMY icon
53
CALL
Bristol-Myers Squibb
BMY
$131B
$253K 0.06%
+179,500
New +$9.14M
RLYP
54
DELISTED
RELYPSA INC COM
RLYP
$253K 0.06%
+10,134
New +$208K
SCAI
55
DELISTED
Surgical Care Affiliates, Inc.
SCAI
$238K 0.05%
+6,824
New +$209K
OCR
56
DELISTED
OMNICARE INC
OCR
$236K 0.05%
+3,902
New +$223K
BHC icon
57
Bausch Health
BHC
$2.21B
$230K 0.05%
1,961
+46
+2% +$5.04K
BLUE
58
DELISTED
bluebird bio
BLUE
$195K 0.04%
717
+247
+53% +$69K
MGNX icon
59
MacroGenics
MGNX
$255M
$74K 0.02%
+2,684
New +$70.2K
AAPL icon
60
Apple
AAPL
$4.56T
– –
-313,376
Closed -$5.34M
AGIO icon
61
Agios Pharmaceuticals
AGIO
$1.91B
– –
-6,366
Closed -$178K
CI icon
62
Cigna
CI
$72.7B
– –
-6,191
Closed -$476K
JCI icon
63
Johnson Controls International
JCI
$93.6B
– –
-94,391
Closed -$4.1M
LOW icon
64
Lowe's Companies
LOW
$122B
– –
-147,072
Closed -$7M
MOH icon
65
Molina Healthcare
MOH
$10B
– –
-7,712
Closed -$275K
MRK icon
66
CALL
Merck
MRK
$317B
– –
-14,672
Closed -$3K
MRK icon
67
Merck
MRK
$317B
– –
-12,534
Closed -$569K
MTG icon
68
MGIC Investment
MTG
$6.21B
– –
-471,629
Closed -$3.43M
MYGN icon
69
CALL
Myriad Genetics
MYGN
$304M
– –
-6,000
Closed -$3K
SCHW
70
Charles Schwab
SCHW
$187B
– –
-220,410
Closed -$4.66M
TDC icon
71
Teradata
TDC
$2.51B
– –
-69,917
Closed -$3.88M
TEX icon
72
Terex
TEX
$7.47B
– –
-131,123
Closed -$4.41M
VIPS icon
73
Vipshop
VIPS
$7.4B
– –
-731,230
Closed -$4.15M
VTRS icon
74
Viatris
VTRS
$19B
– –
-7,188
Closed -$274K
WAT icon
75
CALL
Waters Corp
WAT
$39.2B
– –
-10,100
Closed -$15K
1 2
3
4

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q4 2013 Portfolio in Review

As of Q4 2013, Partner Investment Management held 93 positions worth $441M, up 17% from $375M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Partner Investment Management deployed $26.2M of net new capital in Q4 2013, opening 22 new positions and adding to 21 existing holdings. Its largest new stake was Bristol-Myers Squibb: 662,798 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 28% a quarter earlier, followed by Communication Services and Real Estate.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $16.1M trimmed.

  • Partner Investment Management's largest Q4 2013 buy was Bristol-Myers Squibb: 662,798 shares worth $35.2M.
  • Partner Investment Management added most to Allergan plc in Q4 2013, an estimated $16M increase.
  • Partner Investment Management's biggest Q4 2013 reduction was Thermo Fisher Scientific, cutting an estimated $16.1M.
  • Partner Investment Management fully exited CAMERON INTERNATIONAL CORPORATION in Q4 2013, selling an estimated $11M.
  • Partner Investment Management's ten largest holdings make up 49% of its $441M portfolio in Q4 2013.
  • Partner Investment Management opened 22 new positions and closed 33 in Q4 2013.
  • Partner Investment Management's portfolio value rose 17% quarter-over-quarter to $441M.

Based on Partner Investment Management's 13F filing for Q4 2013, filed 14 Feb 2014.